Genelux (GNLX) Long-Term Deferred Tax (2022 - 2025)

Genelux (GNLX) posted quarterly Long-Term Deferred Tax of $93.7 million for Q4 2025, up 419514.87% quarter-over-quarter from $22330.0 in Q4 2023.

Genelux (GNLX) Long-Term Deferred Tax (2022 - 2025) Analysis & Trends

Genelux's Long-Term Deferred Tax history runs 3 years deep, the most recent figure standing at $93.7 million for Q4 2025.

In Q4 2025, Long-Term Deferred Tax changed N/A year-over-year to $93.7 million; the TTM figure through Dec 2025 stood at $93.7 million (changed N/A YoY), while the FY2025 annual figure was $93.7 million, changed N/A from the prior year.
Long-Term Deferred Tax for Q4 2025 stood at $93.7 million, up from $22330.0 in the prior quarter.
The five-year high for Long-Term Deferred Tax was $93.7 million in Q4 2025, with the low at $22330.0 in Q4 2023.
The 3-year median for Long-Term Deferred Tax is $1.6 million (2022), against an average of $31.8 million.
Peak annual rise in Long-Term Deferred Tax reached 98.58% in 2023, while the deepest fall reached 98.58% in 2023.
Genelux's Long-Term Deferred Tax stood at $1.6 million in 2022, then slumped by 98.58% to $22330.0 in 2023, then surged by 419514.87% to $93.7 million in 2025.
Business Quant data shows GNLX's Long-Term Deferred Tax at $93.7 million in Q4 2025, $22330.0 in Q4 2023, and $1.6 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Genelux	119.87 Mn	119.87 Mn	-

Download Data